You are here

Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects

Last updated on February 22, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Gram-Positive Bacterial Infections, Cross Infection
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
8 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female subjects, ≥ 8 years of age and a weight of ≥ 35 kilograms

- Subjects with selected culture-positive infections caused by a multiple
antibiotic-resistant pathogen presumed to be susceptible to tigecycline

- Subjects who have failed or are intolerant of other available appropriate antibiotic
therapies or whose pathogens are resistant to other available antibiotics

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects who are moribund with an expected survival of less than 2 weeks.

- Subjects who have been designated as "Do Not Resuscitate", unless it is anticipated
within a reasonable degree of medical certainty that they can achieve benefit from
potentially curative antibiotic therapy

- Known or suspected hypersensitivity to tigecycline, tetracyclines, or other compounds
related to this class of antibacterial agents

NCT00081744
Pfizer
Completed
Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Appendicitis, Cholecystitis, Cross Infection, Diverticulitis, Peritonitis
NCT00195351
All Genders
18+
Years
Multiple Sites
Gram-Positive Bacterial Infections, Escherichia Coli Infections, Klebsiella Infections
NCT00167999
All Genders
15+
Years
Seoul,
Gram-Positive Bacterial Infections
NCT00167960
All Genders
18+
Years
Multiple Sites
Gram-Positive Bacterial Infections, Cross Infection
NCT00081744
All Genders

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now